10x Genomics Past Earnings Performance
Past criteria checks 0/6
10x Genomicshan disminuido a un ritmo medio anual de -10.5%, mientras que en la industria Life Sciences los ingresos han sido de growing a 20.7% anuales. Los ingresos han sido growing a una tasa media anual de 26.2%.
Key information
-10.5%
Earnings growth rate
32.2%
EPS growth rate
| Life Sciences Industry Growth | 21.5% |
| Revenue growth rate | 25.3% |
| Return on equity | -34.4% |
| Net Margin | -41.2% |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Recent updates
Here's Why We're Not Too Worried About 10x Genomics' (NASDAQ:TXG) Cash Burn Situation
Feb 05
10x Genomics: Sales Are Growing At A Rapid Rate, But So Are Expenses
Jan 20Revenues Tell The Story For 10x Genomics, Inc. (NASDAQ:TXG) As Its Stock Soars 31%
Dec 22We're Hopeful That 10x Genomics (NASDAQ:TXG) Will Use Its Cash Wisely
Nov 03Here's Why We're Not Too Worried About 10x Genomics' (NASDAQ:TXG) Cash Burn Situation
Aug 04Why Investors Shouldn't Be Surprised By 10x Genomics, Inc.'s (NASDAQ:TXG) P/S
Jun 04At US$52.43, Is 10x Genomics, Inc. (NASDAQ:TXG) Worth Looking At Closely?
Apr 2910x Genomics, Inc. (NASDAQ:TXG) Shares Could Be 28% Below Their Intrinsic Value Estimate
Mar 24We're Interested To See How 10x Genomics (NASDAQ:TXG) Uses Its Cash Hoard To Grow
Feb 02Is Now The Time To Look At Buying 10x Genomics, Inc. (NASDAQ:TXG)?
Jan 12An Intrinsic Calculation For 10x Genomics, Inc. (NASDAQ:TXG) Suggests It's 39% Undervalued
Dec 2210x Genomics: No Signs Of A Growth Turnaround, Heavy Bearish Momentum
Oct 12Here's Why We're Not Too Worried About 10x Genomics' (NASDAQ:TXG) Cash Burn Situation
Oct 0510x Genomics cut to Sell at Goldman Sachs on slower sales ramp
Aug 1810x Genomics: Still Expensive, No Profitability In Sight, And Insiders Are Still Selling
Jul 3010x Genomics guides to Q2 revenues below consensus; shares down 13% after hours
Jul 14Revenue & Expenses BreakdownBeta
How 10x Genomics makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 619 | -255 | 336 | 268 |
| 30 Sep 23 | 591 | -223 | 333 | 269 |
| 30 Jun 23 | 568 | -172 | 327 | 269 |
| 31 Mar 23 | 536 | -174 | 315 | 269 |
| 31 Dec 22 | 516 | -166 | 296 | 264 |
| 30 Sep 22 | 504 | -167 | 289 | 264 |
| 30 Jun 22 | 498 | -142 | 278 | 251 |
| 31 Mar 22 | 499 | -89 | 267 | 234 |
| 31 Dec 21 | 490 | -58 | 258 | 212 |
| 30 Sep 21 | 459 | -455 | 244 | 190 |
| 30 Jun 21 | 406 | -504 | 233 | 165 |
| 31 Mar 21 | 333 | -533 | 209 | 139 |
| 31 Dec 20 | 299 | -543 | 202 | 123 |
| 30 Sep 20 | 262 | -134 | 185 | 112 |
| 30 Jun 20 | 251 | -78 | 166 | 104 |
| 31 Mar 20 | 264 | -49 | 154 | 94 |
| 31 Dec 19 | 246 | -31 | 131 | 83 |
| 30 Sep 19 | 221 | -100 | 119 | 68 |
| 30 Jun 19 | 197 | -105 | 105 | 57 |
| 31 Mar 19 | 170 | -105 | 94 | 51 |
| 31 Dec 18 | 146 | -112 | 88 | 48 |
| 31 Dec 17 | 71 | -19 | 47 | 32 |
Beneficios de calidad: TXG actualmente no es rentable.
Creciente margen de beneficios: TXG actualmente no es rentable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Tendencia de beneficios: TXG no es rentable, y las pérdidas han aumentado en los últimos 5 años a un ritmo de 10.5% al año.
Acelerando crecimiento: No se puede comparar el crecimiento de los beneficios de TXG en el último año con su media de 5 años, ya que actualmente no es rentable.
Beneficios vs. Industria: TXG no es rentable, por lo que resulta difícil comparar el crecimiento de sus beneficios en el último año con el del sector Life Sciences (-11.4%).
Return on Equity
Alto ROE: TXG tiene un Rendimiento de los fondos propios negativo (-29.97%), ya que actualmente no es rentable.